List view / Grid view
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
US scientists have used mouse models of pancreatic cancer to identify genes used by tumour cells to grow uncontrollably.
The finding is an critical first step towards classifying lesions on the pancreas that are at highest risk of becoming cancerous, enabling their removal before they start to spread.
US researchers discovered a type of cell involved it pancreatic cancer and sheds light on the origin of cancer-associated fibroblasts (CAFs).
A new implant that combines internal radiation and chemotherapy dissolved tumours in mice across multiple models.
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
Researchers analysed the expression of long non-coding RNAs in samples from patients and tumour cell lines, identifying a group of genes with augmented expression in pancreatic cancer.
A new study has shown that it is possible to reverse key process that allows pancreatic cancer cells to grow and spread around the body.
Scientists have discovered a new strategy that can make pancreatic tumours visible to the immune systems of mice and vulnerable to immune attack.
An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.